

REMARKS

Claims 1 – 9 are pending in the application.

By way of this amendment, the specification is amended to append to the end of the specification a Sequence Listing of those sequences appearing in paragraphs [0054] (SEQ ID NO:1) and [0063] (SEQ ID NO:2) of the published application. In addition, the specification has been amended to correct two obvious typographical errors in paragraph [0054].

In paragraph [0054], the amino acid sequences shown having three-letter designations for both the W-peptide (SEQ ID NO:1) and its isoform inadvertently omit the fourth amino acid, methionine (Met). The amino acid sequences with the single-letter designations, which are also shown in paragraph [0054], are correct and include the fourth amino acid methionine (M), evidencing the obvious typographical error. As further evidence of this obvious error, provided herewith are copies of the catalogue pages from the commercial source (Phoenix Pharmaceuticals, Inc.) for these two peptides. As can be seen in the catalogue entries, the sequence for the W-peptide is Trp-Lys-Tyr-Met-Val-Met-NH₂ and the sequence for the isoform is Trp-Lys-Tyr-Met-Val-D-Met-NH₂. No new matter has been added.

The Sequence Listing is provided herewith in computer readable form (as an ASCII text file) only, since this amendment is being filed via the USPTO's electronic filing system (EFS). No new matter has been added.

Applicants submit that the application is in condition for substantive examination. The Examiner may call the undersigned at 302-885-9129, if a telephonic interview would be helpful.

Respectfully submitted,

Date: 1 August 2008

/Robin S. QUARTIN, Reg. No. 45,028/
Robin S. Quartin, Ph.D.
Attorney for Applicant
Registration No. 45,028
(302) 885-9129

Enclosures:
Catalogue entries for WKYMVM-NH₂ and WKYMVM